ATAI Life Sciences

Biotech · Berlin, DE

Berlin biotech platform developing psychedelic and other therapeutics for mental health disorders.

Founders

Christian Angermayer (Germany · ♂) — A German entrepreneur and investor and proponent of the psychedelic renaissance, he founded ATAI Life Sciences in 2018 to develop psychedelic and other compounds for mental-health disorders.
Florian Brand (Germany · ♂) — An operator who had worked with Angermayer before, he co-founded ATAI and became CEO to build out its psychedelic mental-health drug pipeline.
Lars Wilde (Germany · ♂) — Co-founded ATAI Life Sciences as a key operator alongside Angermayer and Brand.

Date	Round	Amount
Nov 2020	Series C Berlin mental-health biotech ATAI Life Sciences raised a $125M Series C round co-led by Apeiron Investment Group, Peter Thiel and Catalio Capital Management.	$125M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.